; Intarcia Therapeutics, Inc. – Product Pipeline Review – Q1 2011
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Intarcia Therapeutics, Inc. – Product Pipeline Review – Q1 2011

VIEWS: 1 PAGES: 42

Intarcia Therapeutics, Inc. – Product Pipeline Review – Q1 2011 Summary Global Market Direct’s pharmaceuticals report, “Intarcia Therapeutics, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Intarcia Therapeutics, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Intarcia Therapeutics, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Intarcia Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Intarcia Therapeutics, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Intarcia Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Intarcia Therapeutics, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Intarcia Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in

More Info
  • pg 1
									Intarcia Therapeutics, Inc. – Product Pipeline Review –
                        Q1 2011
                                                                                          Reference Code: GMDHC1205CDB

                                                                                                Publication Date: MAY 2011




Intarcia Therapeutics, Inc. – Product Pipeline Review – Q1 2011                             GMDHC1205CDB / Published MAY 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                Page(1)
Intarcia Therapeutics, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                        4
List of Figures                                                                                                       4
Intarcia Therapeutics, Inc. Snapshot                                                                                  5
    Intarcia Therapeutics, Inc. Overview                                                                              5
    Key Information                                                                                                   5
    Key Facts                                                                                                         5
Intarcia Therapeutics, Inc. – Research and Development Overview                                                       6
    Key Therapeutic Areas                                                                                             6
Intarcia Therapeutics, Inc. – Pipeline Review                                                                         8
    Pipeline Products by Stage of Development                                                                         8
    Pipeline Products – Monotherapy                                                                                   9
    Pipeline Products – Combination Treatment Modalities                                                             10
Intarcia Therapeutics, Inc. – Pipeline Products Glance                                                               11
    Intarcia Therapeutics, Inc. – Late Stage Pipeline                                                                11
         Phase III Products/Combination Treatment Modalities                                                         11
    Intarcia Therapeutics, Inc. Clinical Stage Pipeline Products                                                     12
         Phase II Products/Combination Treatment Modalities                                                          12
         Phase I Products/Combination Treatment Modalities                                                           13
    Intarcia Therapeutics, Inc.–Early Stage Pipeline Products                                                        14
         Discovery Products/Combination Treatment Modalities                                                         14
Intarcia Therapeutics, Inc. – Drug Profiles                                                                          15
    Atamestane + Toremifene                                                                                          15
         Product Description                                                                                         15
         Mechanism of Action                                                                                         15
         R&D Progress                                                                                                15
    ITCA 650                                                                                                         16
         Product Description                                                                                         16
         Mechanism of Action                                                                                         16
         R&D Progress                                                                                                16
    Biomed 101                                                                                                       17
         Product Description                                                                                         17
         Mechanism of Action                                                                                         17
         R&D Progress                                                                                                17
    ITCA 638                                                                                                         18
         Product Description                                                                                         18
         Mechanism of Action                                                                                         18
         R&D Progress                                                                                                18
    ITCA 638 + Ribavirin                                                                                             19
         Product Description                                                                                         19
         Mechanism of Action                                                                                         19
         R&D Progress                                                                                                19
    ITCA 880                                                                                                         21
         Product Description                                                                                         21
         Mechanism of Action                                                                                         21
         R&D Progress                                                                                                21




Intarcia Therapeutics, Inc. – Product Pipeline Review – Q1 2011                           GMDHC1205CDB / Published MAY 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(2)
Intarcia Therapeutics, Inc. – Product Pipeline Review



    ITCA 884                                                                                                         22
         Product Description                                                                                         22
         Mechanism of Action                                                                                         22
         R&D Progress                                                                                                22
    Intarcia Therapeutics, Inc. – Pipeline Analysis                                                                  23
    Intarcia Therapeutics, Inc. – Pipeline Products by Therapeutic Class                                             23
    Intarcia Therapeutics, Inc. - Pipeline Products By Target                                                        24
    Intarcia Therapeutics, Inc. – Pipeline Products by Route of Administration                                       25
    Intarcia Therapeutics, Inc. – Pipeline Products by Molecule Type                                                 26
Intarcia Therapeutics, Inc. – Recent Pipeline Updates                                                                27
Intarcia Therapeutics, Inc. - Dormant Projects                                                                       28
Intarcia Therapeutics, Inc. - Discontinued Pipeline Products                                                         29
    Discontinued Pipeline Product Profiles                                                                           29
         Atamestane + Toremifene                                                                                     29
Intarcia Therapeutics, Inc. – Locations And Subsidiaries                                                             30
    Head Office                                                                                                      30
Financial Deals Landscape                                                                                            31
    Intarcia Therapeutics, Inc., Deals Volume Summary, 2004 to YTD 2011                                              31
    Intarcia Therapeutics, Inc., Deals Summary By Region, 2004 to YTD 2011                                           32
    Intarcia Therapeutics, Inc., Deals Summary, 2004 to YTD 2011                                                     33
    Intarcia Therapeutics, Inc. Detailed Deal Summary                                                                34
         Venture Financing                                                                                           34
         Intarcia Therapeutics Secures $50 Million In Series B Financing                                             34
         Intarcia Therapeutics Secures $50 Million In Series E Financing                                             36
         BioMedicines Secures $38 Million In Financing                                                               38
         Equity Offering                                                                                             40
         Intarcia Therapeutics Withdraws Initial Public Offering                                                     40
Appendix                                                                                                             41
    Methodology                                                                                                      41
         Coverage                                                                                                    4
								
To top